Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Withdrawn 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4Observational 2

Sponsor

Cancer Type

Endocrine 5NET 4Gastrointestinal 2

Conditions

Neuroendocrine Tumors 4Serotonin Syndrome 1Diarrhea 1Carcinoid Tumor 1

Interventions

lutetium Lu 177 dotatate 41Everolimus 38Magnetic Resonance Spectroscopy 18Temozolomide 17lanreotide 16gallium Ga 68 dotatate 15Octreotide 14pembrolizumab 13Nivolumab 13Capecitabine 12cabozantinib 11177Lu-octreotide, DOTA(0)-Tyr(3)- 11surufatinib 9pasireotide 9Sunitinib 9Specimen Handling 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9Lutetium-177 8Carboplatin 8amino-acid, glucose, and electrolyte solution 6Ipilimumab 6Ga(III)-DOTATOC 6Fluorodeoxyglucose F18 6Etoposide 6Cisplatin 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5copper dotatate CU-64 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × telotristat ethyl × NET × Clear all
NCT04810091 2026-03-09

Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor

M.D. Anderson Cancer Center

Phase 3 Active not recruiting
79 enrolled 24 charts
EndocrineNET

Neuroendocrine Tumors

NCT04543955 2023-06-27

Telotristat With Lutathera in Neuroendocrine Tumors

University of Kentucky

Phase 2 Terminated
1 enrolled 4 charts
EndocrineNET

Neuroendocrine Tumors

NCT04713202 2023-02-10

NET-PACS

Big Ten Cancer Research Consortium

Phase 2 Withdrawn
EndocrineNET

Diarrhea, Neuroendocrine Tumors, Serotonin Syndrome

NCT04672876 2021-12-17

Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors

University of Chicago

Phase 2 Withdrawn
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡